Pharmafile Logo
Pharmafocus logo
Advanced Search

Merck

Showing 15 posts of 363 posts found.

acute_leukemia-all

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy

August 12, 2024
Research and Development Corporate, Curon Biopharmaceuticals, Merck, Oncology, b-cells

Merck have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire CN201, a …

News
Lung xray image

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

August 7, 2024
Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …

News

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma

July 29, 2024
Research and Development ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma

Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …

News

FDA approves Merck’s Capvaxive for prevention of pneumococcal disease

June 18, 2024
Medical Communications Capvaxive, FDA, Infections and infestations, Merck, pneumonia

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

News

Merck to acquire EyeBio for an upfront $1.3bn

May 31, 2024
Business Services EyeBio, Merck, Opthalmology, acquisition, ophthalmology

Merck, known as MSD outside of the US and Canada, and EyeBiotech Limited, have announced that the two companies have …

News

Merck shares data from phase 3 trial of Keytruda for TNBC treatment

May 29, 2024
Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda

Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …

News

Merck to acquire Mirus Bio for $600m

May 23, 2024
Business Services Merck, Pharmacy, acquisition, gene therapies

Merck has announced that it has signed a definitive agreement to acquire Mirus Bio for $600m.

News

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024
Research and Development Gastric, MSD, Merck, Oncology, keytruda

Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …

News

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

April 10, 2024
Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …

News

FDA approves Merck’s Winrevair for PAH treatment

March 27, 2024
Medical Communications Cardiology, FDA, Merck, Winrevair, pulmonary arterial hypertension

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

News

Merck shares results for Keytruda in cervical cancer treatment

March 18, 2024
Research and Development Merck, Oncology, cervical cancer, keytruda, women's health

Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-A18 trial, …

News

Merck plans to conduct trials for HPV vaccines

March 13, 2024
Research and Development Immunology, Merck, vaccines

Merck, known as MSD outside of the US and Canada, has announced that it is planning to initiate clinical development …

News

Merck completes acquisition of Harpoon Therapeutics for $650m

March 12, 2024
Business Services Harpoon Therapeutics, Merck, Oncology, lung cancer

Merck, known as MSD outside of the US and Canada, has announced that it has completed the acquisition of Harpoon …

News

Gilead and Merck share data from phase 2 trial of HIV treatment

March 7, 2024
Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …

News

Merck to acquire Harpoon Therapeutics for approximately $680m

January 10, 2024
Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition

Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026